Hyderabad-based Dr Reddy's Laboratories informed the stock exchanges that the US Food and Drug Administration (USFDA) has completed the audit of its formulations at unit II in Srikakulum's special economic zone (SEZ) in Andhra Pradesh on Thursday.
According to the compnay, the USFDA has made no observations after the inspection.
In April, the US drug regulator had inspected Dr Reddy's active pharmaceutical ingredients (APIs) manufacturing unit at the same SEZ plant in Srikakulam with no observations. After the inspection of yet another API facility at Srikakulam in the month of April, the USFDA had issued Form 483 after making two observations.
The USFDA